ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer
Fierce Pharma
JUNE 3, 2024
Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. | Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too.
Let's personalize your content